Arrhythmias & electrophysiologyRandomised controlled trial
Efficacy of a web-based healthcare innovation to advance the quality of life and care of patients with an implantable cardioverter defibrillator (ACQUIRE-ICD): a randomized controlled trial
- Randomised controlled trial
- national
- multi-site
- two-arm
- non-blinded
- superiority
Authors' conclusion
The web-based intervention as supplement to usual care did not improve patient device acceptance nor symptoms of anxiety and depression compared with usual care.
Study context
- Population
- First-time implantable cardioverter defibrillator (ICD) recipients from all 6 implantation centres in Denmark
- Participants
- 478 recipients
- Comparison
- Web-based intervention + usual care vs usual care
- Primary endpoint
- Patient device acceptance by Florida Patient Acceptance Survey (FPAS; 0-100, higher = higher acceptance)
- Follow-up
- 12 months after implantation
Primary result
As reported in the abstract
Device acceptance (FPAS, 0-100) · 12 months
Device acceptance not different between groups
B = −2.67, 95% CI (−5.62, 0.29), P = 0.08
Secondary outcomes
Depressive symptoms
- No significant treatment effect
- B = −0.49, 95% CI (−1.19; 0.21), P = 0.17
Anxiety symptoms
- No significant treatment effect
- B = −0.39, 95% CI (−0.96; 0.18), P = 0.18
Original publication
Efficacy of a web-based healthcare innovation to advance the quality of life and care of patients with an implantable cardioverter defibrillator (ACQUIRE-ICD): a randomized controlled trial. Europace. Published 21 August 2023. doi:10.1093/europace/euad253
Summarised from the published abstract; every number is checked against it